Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Chemical Communications

• Publication date

  2017-03-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1039/c7cc01459gPMID 28304025PMCID PMC5468790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Control of an Unusual Photo-Claisen Rearrangement in Coumarin Caged Tamoxifen through an Extended Spacer

  2017cited by this paper
• An Overview Of Photosubstitution Reactions Of Ru(II) Imine Complexes And Their Application In Photobiology And Photodynamic Therapy.

  2017cited by this paper
• Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage.

  2017cited by this paper
• Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer

  2016cited by this paper
• Selective Release of Aromatic Heterocycles from Ruthenium Tris(2-pyridylmethyl)amine with Visible Light.

  2016cited by this paper
• Luminescent and Photoactive Transition Metal Complexes as Biomolecular Probes and Cellular Reagents

  2015cited by this paper
• A luminescent ruthenium(II) complex for light-triggered drug release and live cell imaging.

  2015cited by this paper
• Insect P450 inhibitors and insecticides: challenges and opportunities.

  2015cited by this paper
• New Ru(II) complexes for dual photoreactivity: ligand exchange and (1)O2 generation.

  2015cited by this paper
• Conversion of abiraterone to D4A drives antitumor activity in prostate cancer

  2015cited by this paper
• Synthetic peptides caged on histidine residues with a bisbipyridyl ruthenium(II) complex that can be photolyzed by visible light.

  2015cited by this paper
• Combination of Ru(ii) complexes and light: new frontiers in cancer therapy

  2015cited by this paper
• Structures of Human Steroidogenic Cytochrome P450 17A1 with Substrates*

  2014cited by this paper
• Unusually Efficient Pyridine Photodissociation from Ru(II) Complexes with Sterically Bulky Bidentate Ancillary Ligands

  2014cited by this paper
• N‐substituted Piperazinopyridylsteroid Derivatives as Abiraterone Analogues Inhibit Growth and Induce Pro‐apoptosis in Human Hormone‐independent Prostate Cancer Cell Lines

  2013cited by this paper
• Molecular Pathways Molecular Pathways : Inhibiting Steroid Biosynthesis in Prostate Cancer

  2013cited by this paper
• Spontaneous formation in the dark, and visible light-induced cleavage, of a Ru-S bond in water: a thermodynamic and kinetic study.

  2013cited by this paper
• Strained ruthenium complexes are potent light-activated anticancer agents.

  2012cited by this paper
• Human Steroid Biosynthesis for the Oncologist

  2012cited by this paper
• Evidence for steroidogenic potential in human prostate cell lines and tissues.

  2012cited by this paper
• Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy

  2012cited by this paper
• CYTOCHROME P450 17A1 STRUCTURES WITH PROSTATE CANCER DRUGS ABIRATERONE AND TOK-001

  2011cited by this paper
• CYP17 inhibitors for prostate cancer therapy.

  2011cited by this paper
• The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

  2011cited by this paper
• [Ru(bpy)2(5-cyanouracil)2]2+ as a potential light-activated dual-action therapeutic agent.

  2011cited by this paper
• Interactions of cytochrome P450s with their ligands.

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Light activation of a cysteine protease inhibitor: caging of a peptidomimetic nitrile with Ru(II)(bpy)2.

  2011cited by this paper
• Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine.

  2009cited by this paper
• Illuminating the chemistry of life: design, synthesis, and applications of "caged" and related photoresponsive compounds.

  2009cited by this paper
• Caged Amino Acids for Visible‐Light Photodelivery

  2008cited by this paper
• Mammalian cytochromes P450--importance of tissue specificity.

  2007cited by this paper
• Cytochromes P450 and metabolism of xenobiotics

  2001cited by this paper
• The First Observation and Full Characterization of All Atropisomers and Their Allowed Interconversions in an Octahedral Bis(bipyridine)ruthenium(II) Complex with Two Lopsided Bicyclic Ligands, as Studied by 2D NMR Techniques at Variable Temperature.

  1999cited by this paper
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications

  1998cited by this paper
• Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis.

  1995cited by this paper
• Steric ligand effects of six bidentate bipyridyl ligands

  1993cited by this paper
• Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy.

  1978cited by this paper

• Spatiotemporal control of prodrug activation through external stimuli for effective and safe on-site release in solid tumors: From current advances to future perspectives.

  2026cites this paper
• Abiraterone organotin complexes: Synthesis and biological activity

  2026cites this paper
• Structure over States: Planarity, Not Energy, Dictates Photoactivation in Ru(II) PACT Agents

  2025cites this paper
• Ru-terpyridine complexes containing clotrimazole as potent photoactivatable selective antifungal agents.

  2024cites this paper
• Ru(II) Oligothienyl Complexes with Fluorinated Ligands: Photophysical, Electrochemical, and Photobiological Properties.

  2024cites this paper
• Modulating Excited State Properties and Ligand Ejection Kinetics in Ruthenium Polypyridyl Complexes Designed to Mimic Photochemotherapeutics.

  2024cites this paper
• The Impact of Inorganic Systems and Photoactive Metal Compounds on Cytochrome P450 Enzymes and Metabolism: From Induction to Inhibition

  2024cites this paper
• Photo-responsive hydrogels based on a ruthenium complex: synthesis and degradation.

  2024cites this paper
• Control of metalloenzyme activity using photopharmacophores.

  2024cites this paper
• Ruthenium complexes with abiraterone acetate as antiproliferative agents.

  2024cites this paper
• Mixed Ru(II)-Ir(III) Complexes as Photoactive Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4.

  2024cites this paper
• Ru(II) Phenanthroline-Based Oligothienyl Complexes as Phototherapy Agents.

  2023cites this paper
• Ruthenium(II) Polypyridyl-Based Photocages for an Anticancer Phytochemical Diallyl Sulfide: Comparative Dark and Photoreactivity Studies of Caged and Precursor Uncaged Complexes.

  2023cites this paper
• Low-Temperature Observation of the Excited-State Decay of Ruthenium-(Mono-2,2′:6′,2″-Terpyridine) Ions with Innocent Ligands: DFT Modeling of an 3MLCT–3MC Intersystem Crossing Pathway

  2023cites this paper
• Intraligand Excited States Turn a Ruthenium Oligothiophene Complex into a Light-Triggered Ubertoxin with Anticancer Effects in Extreme Hypoxia.

  2022cites this paper
• A Lock‐and‐Kill Anticancer Photoactivated Chemotherapy Agent †

  2022cites this paper
• Acetonitrile Ligand Photosubstitution in Ru(II) Complexes Directly from the 3MLCT State.

  2022cites this paper
• Ru(II) photocages enable precise control over enzyme activity with red light

  2022cites this paper
• Balancing the interplay between ligand ejection and therapeutic window light absorption in ruthenium polypyridyl complexes.

  2022cites this paper
• Photocytotoxicity and photoinduced phosphine ligand exchange in a Ru(ii) polypyridyl complex

  2022cites this paper
• Effect of the electronic structure on the robustness of ruthenium(ii) bis-phenanthroline compounds for photodissociation of the co-ligand: synthesis, structural characterization, and density functional theory study

  2021cites this paper
• Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: from molecular design to application.

  2021cites this paper
• Fine‐Feature Modifications to Strained Ruthenium Complexes Radically Alter Their Hypoxic Anticancer Activity†

  2021cites this paper
• Photorelease of a metal-binding pharmacophore from a Ru(II) polypyridine complex.

  2021cites this paper
• Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4.

  2021cites this paper
• The Development of Ru(II)-Based Photoactivated Chemotherapy Agents

  2021cites this paper
• Taking phototherapeutics from concept to clinical launch

  2021cites this paper
• Trifluoromethyl substitution enhances photoinduced activity against breast cancer cells but reduces ligand exchange in Ru(ii) complex

  2021cites this paper
• Photofunctional transition metal complexes as cellular probes, bioimaging reagents and phototherapeutics

  2021cites this paper
• Incorporation of potent and selective cytochrome P450 1B1 inhibitors into Ru(II) scaffolds provides unprecedented control over enzyme activity with light

  2021cites this paper
• Unlocking the Potential of Ru(II) Dual‐action Compounds with the Power of the Heavy‐atom Effect †

  2021cites this paper
• Taking phototherapeutics from concept to clinical launch

  2021cites this paper
• Modification of amyloid-beta peptide aggregation via photoactivation of strained Ru(ii) polypyridyl complexes†

  2021cites this paper
• Ru(II)-diimine complexes and cytochrome P450 working hand-in-hand.

  2020cites this paper
• Visible-to-NIR-Light Activated Release: From Small Molecules to Nanomaterials

  2020cites this paper
• Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives

  2020cites this paper
• DDDT_A_275007 5375..5392

  2020cites this paper
• Breaking the barrier: an osmium photosensitizer with unprecedented hypoxic phototoxicity for real world photodynamic therapy

  2020cites this paper
• Toward Optimal Ru(II) Photocages: Balancing Photochemistry, Stability, and Biocompatibility Through Fine Tuning of Steric, Electronic, and Physiochemical Features.

  2020cites this paper
• Light-activated ruthenium (II)-bicalutamide prodrugs for prostate cancer.

  2019cites this paper
• The synthesis and characterization of Re(CO)3 pyca-anthraquinone conjugates

  2019cites this paper
• Non-platinum complexes containing releasable biologically active ligands

  2019cites this paper
• Transition metal complexes as photosensitisers in one- and two-photon photodynamic therapy

  2019cites this paper
• New Designs for Phototherapeutic Transition Metal Complexes

  2019cites this paper
• Luminescent Ruthenium(II) Polypyridine Complexes for a Wide Variety of Biomolecular and Cellular Applications.

  2019cites this paper
• NIR-Light-Driven Generation of Reactive Oxygen Species Using Ru(II)-Decorated Lipid-Encapsulated Upconverting Nanoparticles

  2019cites this paper
• Diastereoselective Synthesis and Two-Step Photocleavage of Ruthenium Polypyridyl Complexes Bearing a Bis(thioether) Ligand

  2019cites this paper
• Ruthenium-cross-linked hydrogels for rapid, visible-light protein release.

  2019cites this paper
• Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.

  2018cites this paper
• Characterization and Biological Activity of a Hydrogen Sulfide-Releasing Red Light-Activated Ruthenium(II) Complex.

  2018cites this paper
• Why develop photoactivated chemotherapy?

  2018cites this paper
• Cyclometalated Ruthenium(II) Complexes Derived from α-Oligothiophenes as Highly Selective Cytotoxic or Photocytotoxic Agents.

  2018cites this paper
• Ru(II) Polypyridyl Complexes Derived from Tetradentate Ancillary Ligands for Effective Photocaging.

  2018cites this paper
• New Ru(ii) complex for dual photochemotherapy: release of cathepsin K inhibitor and 1O2 production.

  2018cites this paper
• Harnessing ruthenium(II) as photodynamic agents: Encouraging advances in cancer therapy

  2018cites this paper
• Photolabile ruthenium complexes to cage and release a highly cytotoxic anticancer agent.

  2018cites this paper
• Ru(ii) polypyridyl complexes as photocages for bioactive compounds containing nitriles and aromatic heterocycles.

  2018cites this paper
• Photochemical Resolution of a Thermally Inert Cyclometalated Ru(phbpy)(N–N)(Sulfoxide)+ Complex

  2018cites this paper
• Effects of the Bidentate Ligand on the Photophysical Properties, Cellular Uptake, and (Photo)cytotoxicity of Glycoconjugates Based on the [Ru(tpy)(NN)(L)]2+ Scaffold

  2018cites this paper
• Photoactivation of imatinib-antibody conjugate using low-energy visible light from Ru(ii)-polypyridyl cages.

  2018cites this paper
• Ru(ii) complexes with diazine ligands: electronic modulation of the coordinating group is key to the design of "dual action" photoactivated agents.

  2018cites this paper
• Stimuli-Responsive Therapeutic Metallodrugs.

  2018cites this paper
• Excited State Dynamics of a Photobiologically Active Ru(II) Dyad Are Altered in Biologically Relevant Environments.

  2017cites this paper
• A Red‐Light‐Activated Ruthenium‐Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells

  2017cites this paper